This study explored the potential of bilirubin as a significant predictor of the therapeutic efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.